Kaliumchloride + Natriumchloride B. Braun

Potassium chloride and sodium chloride, the active ingredients in Kaliumchloride + Natriumchloride B. Braun, are electrolyte supplements presented as an injectable solution for intravenous use. They help correct potassium and sodium deficiencies and support fluid and electrolyte balance in hospitalized patients, particularly in peri‑operative, critical‑care, and renal‑impairment settings.

GNH USA supplies Kaliumchloride + Natriumchloride B. Braun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Kaliumchloride + Natriumchloride is an injectable electrolyte supplement used to restore potassium and sodium balance in clinical settings.

Hypokalemia: restores potassium levels to prevent cardiac arrhythmias. Hyponatremia: replenishes sodium to maintain plasma osmolality. Peri‑operative fluid and electrolyte replacement: provides both ions to support hemodynamic stability during surgery. Acute renal failure management: supplies potassium and sodium while monitoring renal function. Critical care electrolyte management: maintains electrolyte homeostasis in ICU patients.

Administration of the potassium chloride and sodium chloride injection may be associated with several adverse reactions.

Common Side Effects: - Infusion site pain or irritation. - Phlebitis or local inflammation. - Mild hyperkalemia. - Mild hypernatremia. - Nausea. - Headache.

Serious or Rare Side Effects: - Cardiac arrest due to severe hyperkalemia. - Anaphylactic or severe allergic reaction. - Severe hypernatremia with neurologic symptoms such as confusion or seizures. - Life‑threatening arrhythmias. - Extreme electrolyte imbalance requiring emergency intervention.

Careful assessment and monitoring are required when using this injectable electrolyte solution.

Renal impairment: monitor serum potassium and sodium levels closely. Cardiac disease: avoid rapid infusion rates to prevent arrhythmias. Hyperkalemia risk: check baseline potassium before administration. Concomitant potassium‑sparing agents: increase monitoring of electrolytes. Pregnancy and lactation: use only if potential benefit justifies risk. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Electrolyte balance can be altered by several co‑administered medicines.

Major Interactions (Avoid): - ACE inhibitors: may potentiate hyperkalemia. - Potassium‑sparing diuretics (e.g., spironolactone): increase risk of elevated potassium.

Moderate Interactions (Monitor Closely): - Digoxin: altered potassium levels can affect drug toxicity. - Beta‑blockers: combined effect on cardiac conduction. - Loop diuretics: may cause rapid shifts in sodium and potassium requiring close monitoring.